Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to the taxation of intellectual property income. Issues related to foreign country tax administration and extraterritorial taxes. Issues related to IRC sections 11, 41 and 174, 45C, 55, 56A, and 59, 59A, 163(j), 250, 951A, 954(d) and 954(e), and 960(d)(2).
2026 · 2nd Quarter (Apr 1 - June 30)
ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 9, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE WASHINGTON TAX & PUBLIC POLICY GROUP
- Filing UUID
- dc004147-71c8-4300-852f-2417c7ad9561
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.